Lars Mueller, United States of America
University of California San Diego Design LabPresenter of 1 Presentation
GLYCEMIC TRENDS IN PEOPLE WITH TYPE 1 DIABETES BASED ON THEIR TIME OF ADOPTION OF CONTROL-IQ TECHNOLOGY
Abstract
Background and Aims
As advanced hybrid closed-loop systems come to market, the impact of early adopters on real-world glycemic outcomes is debated. We retrospectively explored glycemic trends in T1D users based on their time of adoption of the Tandem Diabetes Care® t:slim X2™ insulin pump with Control-IQ® technology.
Methods
Participants (N=6,233) included T1D users from Tandem’s installed base who had initiated Control-IQ technology between its launch (January 15, 2020) and July 15, 2020. Participants were divided into three groups based on their time of adoption: within 4 weeks (Group A), between 3-4 months (Group B) and 5-6 months (Group C). Glycemic data was retrieved from Tandem’s t:connect® web application for six weeks pre and post use of the system. Pre-post differences were analyzed using T-test or Wilcoxon-signed rank tests.
Results
Compared to other groups, Group A, initiated Control-IQ technology with a significantly higher median time in range (TIR) (64.1%), lower mean sensor glucose (SG) (167 ±30), and more time with SG<70mg/dL (1.1%). After six weeks of Control-IQ technology, all three groups showed significant improvements in TIR, reductions in mean SG, and time with SG>180mg/dL. Groups B and C demonstrated greater increases in TIR (+11%) vs. Group A (+9.4%).
Conclusions
Irrespective of when Control-IQ technology was adopted, significant improvements in TIR were experienced by all groups. These findings also suggest that early adopters of diabetes technology pursue tighter SG control compared to other users. Further exploration of diabetes management behaviors of early adopters of diabetes technology is recommended.